Targets › HER3
4 programs from 4 companies in 22 trials: 15 Phase 2, 6 Phase 1, 1 Phase 3; Oncology; next expected readout Nov 2026.
Tyrosine kinase receptor that, despite substitutions of key catalytic residues in the kinase domain, retains residual catalytic activity enabling autophosphorylation. Functions primarily as a heterodimer, preferentially partnering with ERBB2/HER2, which phosphorylates ERBB3 on specific tyrosine residues and provides the kinase activity required for downstream signaling. (UniProt, P21860)
Open in Phaseline: the race on HER3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sichuan Baili Pharmaceutical | SI-B001 EGFR/HER3 bispecific antibody | EGFR, HER3 | Phase 3 | Non-small Cell Lung Adenocarcinoma; Non-small Cell Lung Cancer; Esophageal Squamous Cell Carcinomas; Head and Neck Squamous Cell Carcinoma … | Nov 2026 |
| Shanghai Junshi Bioscience Co., Ltd. | JS212 for Injection Bispecific antibody-drug conjugate targeting EGFR and HER3 with topoisomerase I inhibitor | EGFR, HER3 | Phase 2 | Advanced Esophageal Squamous Cell Carcinoma; Advanced Malignant Solid Tumors; Advanced Lung Cancer; Metastatic Colorectal Cancer … | Jun 2027 |
| Hangzhou Zhongmei Huadong Pharmaceutical | HDM2024 Antibody-drug conjugate targeting EGFR and HER3 | EGFR, HER3 | Phase 1 | Advanced Solid Tumors | Apr 2027 |
| BioNTech SE | anti-HER3 antibody conjugated to topoisomerase I inhibitor anti-HER3 antibody-drug conjugate with topoisomerase I inhibitor | HER3 | Phase 1 | Non-Small Cell Lung Cancer | Feb 2030 |
Head and Neck Squamous Cell Carcinoma (3) Non-small Cell Lung Cancer (2) Triple-negative Breast Cancer (2) Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations (2) Non-small Cell Lung Adenocarcinoma (1) Esophageal Squamous Cell Carcinomas (1) Non Small Cell Lung Cancer (1) Locally Advanced or Metastatic Epithelial Tumor (1) Squamous Cell Carcinoma of Head and Neck (1) Advanced Solid Tumors (1) Advanced Esophageal Squamous Cell Carcinoma (1) Advanced Malignant Solid Tumors (1)
small molecule (3), mixed (1)
Sichuan Baili Pharmaceutical (1) Hangzhou Zhongmei Huadong Pharmaceutical (1) Shanghai Junshi Bioscience Co., Ltd. (1) BioNTech SE (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.